🇺🇸 FDA
Pipeline program

Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

EFC17600

Phase 3 small_molecule active

Quick answer

Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS for atopic dermatitis is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
atopic dermatitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials